GLP-1 drugs, commonly associated with managing diabetes and obesity, may also offer relief for migraine sufferers. A recent study showed that these medications decreased the number of migraine days reported each month.
This research, unveiled at the European Neurological Society Conference in Herinsky, Finland, indicates promising future applications for these widely used drugs. According to the World Health Organization, around 40 million Americans experience migraines, which can be debilitating, extending beyond mere headaches to include symptoms like nausea and light sensitivity that disrupt daily life.
Notably, prior studies suggest that GLP-1 can lower intracranial pressure, which is believed to play a role in migraines. A group of researchers, including neurologist Simone Braca from Naples, explored whether liraglutide, a GLP-1 receptor agonist, could aid patients suffering from these headaches.
In a trial involving 31 adults—26 of whom were women—participants received daily injections of liraglutide for 12 weeks. Those who met obesity criteria continued their regular migraine medication alongside the treatment. Initially, participants reported having headaches about 20 days a month; by the study’s end, this average dropped to approximately 11 days.
Braca noted that most patients felt improvements within just two weeks, significantly enhancing their quality of life. Interestingly, participants’ weights remained stable during the trial, implying that the headache reduction was likely independent of any weight loss.
While researchers acknowledged that weight loss was minimal and statistically insignificant, migraine relief persisted throughout the study period. Dr. Sue Decotiis, a weight loss specialist, commented on liraglutide, describing it as a ‘middle-aged’ GLP-1 compared to newer alternatives like Ozempic and Munjaro. She pointed out that liraglutide is less effective for weight loss and isn’t commonly utilized for that purpose.
However, the trial had its limitations. There was no control group, and both participants and researchers were aware everyone received liraglutide. About 38% of participants experienced mild gastrointestinal side effects, such as nausea and constipation, but these did not result in anyone discontinuing the treatment.
Future studies are necessary to include other demographics and perhaps compare with individuals who do not have obesity. The team also plans to conduct a randomized, double-blind trial, aiming to assess the impact of other GLP-1 drugs on migraine relief. Understanding whether these alternatives might offer similar benefits—with potentially fewer gastrointestinal issues—could be crucial in future treatment options.
